What is Imcyse?
Imcyse is at the forefront of developing transformative treatments for severe, chronic autoimmune conditions. Leveraging its proprietary Imotope platform, the company engineers synthetic peptides designed to precisely modulate the patient's immune system, aiming to restore immune balance rather than broadly suppress it. This innovative approach underpins a diverse pipeline with active clinical and pre-clinical programs targeting debilitating diseases such as Type 1 Diabetes, Multiple Sclerosis, and Rheumatoid Arthritis. Imcyse's commitment to advancing these therapies is further bolstered by strategic collaborations with leading academic institutions and industry partners.
How much funding has Imcyse raised?
Imcyse has raised a total of $25.6M across 1 funding round:
Series B
$25.6M
Series B (2021): $25.6M with participation from Biogenosis, Life Sciences Partners, SFPI Group, Noshaq, Pfizer, SRIW, K.U.Leuven, and Epimedic
Key Investors in Imcyse
Biogenosis
Biogenosis, operating in the life sciences sector, likely focuses on biotechnology research and development, potentially contributing expertise in biological processes and therapeutic innovation.
Life Sciences Partners
Life Sciences Partners is a prominent venture capital firm specializing in the life sciences sector, known for its investments in innovative healthcare and biotechnology companies at various stages of development.
Pfizer
Pfizer is a global biopharmaceutical leader engaged in the discovery, development, manufacturing, and marketing of medicines and vaccines, indicating a strategic interest in Imcyse's therapeutic advancements and market potential.
What's next for Imcyse?
The substantial enterprise-level funding positions Imcyse for accelerated development and potential commercialization of its pipeline assets. With a clear focus on autoimmune diseases, the company is poised to advance its clinical programs, potentially bringing novel therapeutic options to patients with significant unmet needs. Future growth will likely involve further clinical trial progression, strategic partnerships for broader market access, and continued innovation within the Imotope platform to address a wider spectrum of immune-mediated disorders.
See full Imcyse company page
